Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States
CONCLUSION: Mosunetuzumab is estimated to be cost-effective compared with approved regimens except R-Len for the treatment of adults with R/R FL.PMID:38712895 | DOI:10.1080/13696998.2024.2352820 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 7, 2024 Category: Health Management Authors: Matthew Matasar Javier Sanchez Alvarez H élène Parisé Eric Zuk Danilo Di Maio Sheila Shapouri Eunice Kim Shih-Wen Lin Source Type: research
A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma
CONCLUSION: The ARG-based signature may provide a promising direction for prognosis prediction and treatment optimization for DLBCL patients.PMID:38709202 | DOI:10.1080/14737159.2024.2351465 (Source: Expert Review of Molecular Diagnostics)
Source: Expert Review of Molecular Diagnostics - May 6, 2024 Category: Laboratory Medicine Authors: Mingze Guan Hua Zhao Qi Zhang Li Li Xiaobo Wang Bo Tang Source Type: research
A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma
CONCLUSION: The ARG-based signature may provide a promising direction for prognosis prediction and treatment optimization for DLBCL patients.PMID:38709202 | DOI:10.1080/14737159.2024.2351465 (Source: Cancer Control)
Source: Cancer Control - May 6, 2024 Category: Cancer & Oncology Authors: Mingze Guan Hua Zhao Qi Zhang Li Li Xiaobo Wang Bo Tang Source Type: research
A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma
CONCLUSION: The ARG-based signature may provide a promising direction for prognosis prediction and treatment optimization for DLBCL patients.PMID:38709202 | DOI:10.1080/14737159.2024.2351465 (Source: Expert Review of Molecular Diagnostics)
Source: Expert Review of Molecular Diagnostics - May 6, 2024 Category: Laboratory Medicine Authors: Mingze Guan Hua Zhao Qi Zhang Li Li Xiaobo Wang Bo Tang Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Clinical outcomes of pomalidomide ‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
ConclusionsIn real-world settings, Pom-based, Dara-based, and DPd therapies exhibited favorable efficacy in patients with RRMM. Dara-based therapy yielded superior clinical response and PFS compared to Pom-based therapy. (Source: Cancer Medicine)
Source: Cancer Medicine - May 3, 2024 Category: Cancer & Oncology Authors: Xiaoyan Han,
Xincheng Jiang,
Jingsong He,
Gaofeng Zheng,
Yaqin Xiong,
Yanling Wen,
Yang Yang,
Donghua He,
Qingxiao Chen,
Yi Zhao,
Yi Li,
Wenjun Wu,
Zhen Cai Tags: RESEARCH ARTICLE Source Type: research
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
CONCLUSIONS: Overall analysis of four studies showed a potential benefit for daratumumab in terms of overall survival and progression-free survival and a slight potential benefit in quality of life. Participants treated with daratumumab probably experience increased serious adverse events. There were likely no differences between groups in adverse events (CTCAE grade ≥ 3); however, there are probably more infections (CTCAE grade ≥ 3) in participants treated with daratumumab. We identified six ongoing studies which might strengthen the certainty of evidence in a future update of this review.PMID:38695605 | DOI:10.1002/1...
Source: Cochrane Database of Systematic Reviews - May 2, 2024 Category: General Medicine Authors: Peter Langer Lukas John Ina Monsef Christof Scheid Vanessa Piechotta Nicole Skoetz Source Type: research
The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)
CONCLUSION: The APAC MRDR is providing 'real-world' data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region.PMID:38698331 | DOI:10.1186/s12874-024-02227-0 (Source: Cell Research)
Source: Cell Research - May 2, 2024 Category: Cytology Authors: Naomi Aoki Pin-Yen Chen Wenming Chen Wee Joo Chng Gin Gin Gan Yeow Tee Goh Jian Hou Jeffrey Huang Kihyun Kim Je Jung Lee Jin Lu Zoe K McQuilten Chang Ki Min Elizabeth Moore Laura Oliver Neil A Waters Cameron Wellard Erica M Wood Su-Peng Yeh Andrew Spencer Source Type: research
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
CONCLUSIONS: Overall analysis of four studies showed a potential benefit for daratumumab in terms of overall survival and progression-free survival and a slight potential benefit in quality of life. Participants treated with daratumumab probably experience increased serious adverse events. There were likely no differences between groups in adverse events (CTCAE grade ≥ 3); however, there are probably more infections (CTCAE grade ≥ 3) in participants treated with daratumumab. We identified six ongoing studies which might strengthen the certainty of evidence in a future update of this review.PMID:38695605 | DOI:10.1002/1...
Source: Cochrane Database of Systematic Reviews - May 2, 2024 Category: General Medicine Authors: Peter Langer Lukas John Ina Monsef Christof Scheid Vanessa Piechotta Nicole Skoetz Source Type: research
